deferoxamine has been researched along with Leukemia, Acute Monocytic in 5 studies
Deferoxamine: Natural product isolated from Streptomyces pilosus. It forms iron complexes and is used as a chelating agent, particularly in the mesylate form.
desferrioxamine B : An acyclic desferrioxamine that is butanedioic acid in which one of the carboxy groups undergoes formal condensation with the primary amino group of N-(5-aminopentyl)-N-hydroxyacetamide and the second carboxy group undergoes formal condensation with the hydroxyamino group of N(1)-(5-aminopentyl)-N(1)-hydroxy-N(4)-[5-(hydroxyamino)pentyl]butanediamide. It is a siderophore native to Streptomyces pilosus biosynthesised by the DesABCD enzyme cluster as a high affinity Fe(III) chelator.
| Excerpt | Relevance | Reference |
|---|---|---|
| "Deferoxamine toxicity was immediately suspected and therapy promptly interrupted." | 1.40 | Spectral domain optical coherence tomography findings in early deferoxamine maculopathy: report of two cases. ( Alami, A; Benghiat, FS; Rasquin, F; Van Bol, L, 2014) |
| " We hypothesize that the relatively higher bioavailability of nontransferrin iron in LIT cells, over that in HID cells, determines the differing responses observed under low-iron conditions." | 1.30 | The inability of cells to grow in low iron correlates with increasing activity of their iron regulatory protein (IRP). ( Kovár, J; Kriegerbecková, K; Kühn, LC; Musílková, J; Richardson, V; Seiser, C, 1997) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 2 (40.00) | 18.2507 |
| 2000's | 2 (40.00) | 29.6817 |
| 2010's | 1 (20.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Van Bol, L | 1 |
| Alami, A | 1 |
| Benghiat, FS | 1 |
| Rasquin, F | 1 |
| Ravanat, JL | 1 |
| Douki, T | 1 |
| Duez, P | 1 |
| Gremaud, E | 1 |
| Herbert, K | 1 |
| Hofer, T | 1 |
| Lasserre, L | 1 |
| Saint-Pierre, C | 1 |
| Favier, A | 1 |
| Cadet, J | 1 |
| Silver, BJ | 1 |
| Hamilton, BD | 1 |
| Toossi, Z | 1 |
| Kovár, J | 1 |
| Kühn, LC | 1 |
| Richardson, V | 1 |
| Seiser, C | 1 |
| Kriegerbecková, K | 1 |
| Musílková, J | 1 |
| Scaccabarozzi, A | 1 |
| Arosio, P | 1 |
| Weiss, G | 1 |
| Valenti, L | 1 |
| Dongiovanni, P | 1 |
| Fracanzani, AL | 1 |
| Mattioli, M | 1 |
| Levi, S | 1 |
| Fiorelli, G | 1 |
| Fargion, S | 1 |
5 other studies available for deferoxamine and Leukemia, Acute Monocytic
| Article | Year |
|---|---|
Spectral domain optical coherence tomography findings in early deferoxamine maculopathy: report of two cases.
Topics: Deferoxamine; Female; Humans; Leukemia, Monocytic, Acute; Middle Aged; Retinal Degeneration; Siderop | 2014 |
Cellular background level of 8-oxo-7,8-dihydro-2'-deoxyguanosine: an isotope based method to evaluate artefactual oxidation of DNA during its extraction and subsequent work-up.
Topics: 8-Hydroxy-2'-Deoxyguanosine; Animals; Antioxidants; Artifacts; Cattle; Cell Fractionation; Chelating | 2002 |
Suppression of TNF-alpha gene expression by hemin: implications for the role of iron homeostasis in host inflammatory responses.
Topics: Blood; Culture Media; Deferoxamine; Gene Expression Regulation, Neoplastic; Hemin; Homeostasis; Huma | 1997 |
The inability of cells to grow in low iron correlates with increasing activity of their iron regulatory protein (IRP).
Topics: Biological Transport; Burkitt Lymphoma; Cell Division; Culture Media; Deferoxamine; HeLa Cells; Huma | 1997 |
Relationship between TNF-alpha and iron metabolism in differentiating human monocytic THP-1 cells.
Topics: Binding Sites; Blotting, Northern; Cell Differentiation; Cell Line; Chelating Agents; Deferoxamine; | 2000 |